Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 11 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:10 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 18, 2026 | Jun 23, 2025 | Jun 21, 2024 | Jun 23, 2023 | Jun 21, 2022 |
| Revenue | – | – | – | – | $0 |
| Cost of revenue | – | – | – | – | $0 |
| Research and development | $2.40M | $9.51M | $4.68M | $9.97M | $5.56M |
| Selling, general and administrative | $8.67M | $7.17M | $6.43M | $7.61M | $9.26M |
| Operating income | -$11.1M | -$16.7M | -$12.9M | -$52.2M | -$15.6M |
| Income tax | -$1.70M | -$3.20M | -$1.83M | -$9.54M | -$648.0K |
| Net income | -$7.79M | -$9.57M | -$12.9M | -$42.4M | -$9.82M |
| EPS, basic | $-0.47 | $-0.79 | $-1.35 | $-0.95 | – |
| EPS, diluted | $-0.47 | $-0.79 | $-1.35 | $-0.95 | – |
| Weighted shares, basic | 16.5M | 12.1M | 9.53M | 44.6M | – |
| Weighted shares, diluted | 16.5M | 12.1M | 9.53M | 44.6M | – |
| Margins and growth | |||||
| Revenue growth, year over year | – | – | – | – | −100.0% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 18, 2026 | Jun 23, 2025 | Jun 21, 2024 | Jun 23, 2023 | Jun 21, 2022 |
| Cash and equivalents | $17.0M | $22.1M | $23.0M | $27.9M | $30.3M |
| Short-term investments | – | – | $0 | $15.0K | $13.3M |
| Accounts receivable | – | – | $722.0K | $802.0K | $548.0K |
| Total current assets | $17.4M | $22.7M | $24.0M | $29.3M | $45.5M |
| Property, plant and equipment | $8.00K | $15.0K | $24.0K | $12.2M | $20.9M |
| Goodwill | $8.14M | $8.14M | $8.14M | $8.14M | $13.0M |
| Intangible assets | $41.1M | $41.1M | $41.1M | $41.1M | $69.8M |
| Total assets | $66.7M | $72.0M | $73.3M | $79.1M | $128.6M |
| Total current liabilities | $2.15M | $1.93M | $1.68M | $3.41M | $3.26M |
| Total liabilities | $2.76M | $5.38M | $11.6M | $11.2M | $20.4M |
| Shareholders' equity | $63.9M | $66.6M | $61.7M | $68.0M | $108.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 18, 2026 | Jun 23, 2025 | Jun 21, 2024 | Jun 23, 2023 | Jun 21, 2022 |
| Operating cash flow | -$8.87M | -$14.9M | -$12.3M | -$15.9M | -$17.2M |
| Stock-based compensation | $798.0K | $730.0K | $913.0K | $1.81M | $1.34M |
| Investing cash flow | $0 | $0 | $104.0K | $13.2M | -$3.52M |
| Financing cash flow | $3.71M | $14.0M | $7.36M | $304.0K | $0 |
| Net change in cash | -$5.16M | -$872.0K | -$4.87M | -$2.46M | -$20.6M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 11, 2026 | 21.0M | +52.1% | SEC |
| Jun 15, 2026 | 16.3M | +17.7% | SEC |
| Feb 12, 2026 | 15.5M | +15.3% | SEC |
| Nov 13, 2025 | 15.5M | +52.6% | SEC |
| Aug 11, 2025 | 13.8M | +36.4% | SEC |
| Jun 19, 2025 | 13.8M | +47.1% | SEC |
| Feb 12, 2025 | 13.4M | +42.7% | SEC |
| Nov 13, 2024 | 10.1M | +7.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Mar 31, 2021, from 13F share counts: 1-for-6 in Q3 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.